Borys Hrinczenko, M.D.

Specialties

Oncology - Hematology, Oncology - Medical

Subspecialties

Hematology, Medical Oncology

Board Certification

American Board of Internal Medicine, Hematology, Medical Oncology

Multidisciplinary Team

Thoracic Oncology

Language(s) Spoken

English

Locations

Karmanos Cancer Institute at McLaren Greater Lansing
3520 Forest Rd.
Lansing, MI 48910
Get Directions

Phone:517-975-9500
Fax: 517-975-9520

Call For Appointment

Locations

Karmanos Cancer Institute at McLaren Greater Lansing

3520 Forest Rd.
Lansing, MI 48910
Get Directions

Phone:517-975-9500
Fax: 517-975-9520

Get Directions

Education

Additional Info

Dr. Hrinczenko received his medical degree from SUNY Downstate in New York and completed an internal medicine internship and residency at the Mayo Clinic in Rochester, Minnesota, followed by a fellowship in hematology and medical oncology at the National Institutes Health in Bethesda, Maryland. He has pursued an academic medicine career and his research has focused on the development of novel therapeutic strategies and biomarkers for lung cancer. He has been a principal investigator on more than 50 cancer clinical trials and has more than 100 publications, abstracts, and presentations.

Related News

February 17, 2022
Three Teams, One Home: McLaren, Karmanos, MSU Health Care Bringing the Future of Cancer Care to Lansing

The brightest minds in cancer care are coming together to work side-by-side at the Karmanos Cancer Institute at McLaren Greater Lansing , opening doors to new frontiers in cancer care and research. Opening February 28, the new cancer center is a collaboration between McLaren Greater Lansing, and the Karmanos Cancer Institute, in partnership with MSU Health Care. The partnership will help recruit top clinicians to the region, provide outstanding patient care, and access new life-changing therapies and tr...
Read More

Awards

Fellow, Royal Society of Medicine, London, England
(elected) Alpha Omega Alpha (AOA)
Medical Honor Society
(elected) Phi Kappa Phi – National Academic Honors Society
(elected) Sigma Xi – National Research Honors Society
(elected) Phi Lambda Upsilon – National Chemistry Honors Society
(elected) “Who’s Who in Medicine and Healthcare”; “Who’s Who in the World”; “Who’s Who in America”, 2005-2022

Professional Memberships

American Society of Clinical Oncology

Publications

Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor M, Bennouna J, Leach J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL, “Long-term avelumab treatment in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor,” Future Oncol. 2022 Apr;18(11):1333-1342. Doi: 10.2217/fon-2021-0930. PMID: 35144482.
Gullapalli K, Mosalem O, Varghese M T, Watat K, Hrinczenko, B. (July 16, 2021) “Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma with Small Bowel Metastasis”. Cureus 13(7): e16431. DOI 10.7759/cureus.16431
Vasilescu A, Hrinczenko B, Swain G, Peteu SF, "Exhaled Breath Biomarker Sensing", Biosens Bioelect. 2021 Mar 26;182: 113193. Doi: 10.1016/j.bios. 2021.113193.
Mosalem O, Alsara A, Abu Rous F, Hrinczenko B, "Adenoid cystic carcinoma of the labium oris with rare metastasis to the pleural cavity", BMJ Case Rep. 2021 Jan 7;14(1):e237622. doi: 10.1136/bcr-2020-237622. PMID: 33414116.
Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP. “Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN Solid Tumor study,” Breast Cancer Res Treat. 2018 Feb; 167(3): 671-686. doi: 10.1007/s10549-017-4537-5. PMID: 29063313.

Provider Profile:
Borys Hrinczenko, M.D.